OTC$SMNR
Semnur Pharmaceuticals Inc · Q1 2025 earnings
Q1 2025 earnings · · Investor relations
Briefing
Semnur Pharmaceuticals reported Q1 2025, net loss of $194.6M.
For Q1 2025, Semnur Pharmaceuticals reported a net loss of $194.6M. Management discussed operating trends, liquidity, and outlook in the linked filing.
- Net loss $194.6M.
- Semnur Pharmaceuticals highlights segment execution and capital priorities.
- Semnur Pharmaceuticals highlights segment execution and capital priorities.
Headline financials
Revenue & EPS history
Denali Capital Acquisition-A · Revenue · Quarterly
$50M
Forward guidance
The filing discusses Semnur Pharmaceuticals's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.
Tailwinds
- Semnur Pharmaceuticals discussed operating priorities and capital allocation for upcoming periods.
- Liquidity and balance-sheet capacity support ongoing operations.
Headwinds
- GAAP profitability remained under pressure in Q1 2025.
- Macro, input costs, and FX may pressure margins quarter to quarter.
- Segment mix and one-time items can affect year-over-year comparability.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
+0.2%
Avg return
Earnings day
—
Avg return
5 days after
—
Avg return
30 days after
63%
5 / 8 earnings
Positive
+8.5%
Q4 2023
Best reaction
-8.0%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2025 | — | — | — | |
| Q3 2024 | -0.8% | — | — | |
| Q2 2024 | +1.6% | — | — | |
| Q1 2024 | -8.0% | — | — | |
| Q4 2023 | +8.5% | — | — | |
| Q3 2023 | +0.1% | — | — | |
| Q2 2023 | +0.2% | — | — | |
| Q1 2023 | +0.0% | — | — | |
| Q4 2022 | +0.2% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro